Effects of ritobegron (KUC-7483), a novel β<sub>3</sub>-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine
-
- Maruyama Itaru
- Kissei Pharmaceutical Co., Ltd., Japan
-
- Yonekubo Saori
- Kissei Pharmaceutical Co., Ltd., Japan
-
- Tatemichi Satoshi
- Kissei Pharmaceutical Co., Ltd., Japan
-
- Maruyama Kazuyasu
- Kissei Pharmaceutical Co., Ltd., Japan
-
- Hoyano Yuji
- Kissei Pharmaceutical Co., Ltd., Japan
-
- Yamazaki Yoshinobu
- Kissei Pharmaceutical Co., Ltd., Japan
-
- Kusama Hiroshi
- Kissei Pharmaceutical Co., Ltd., Japan
この論文をさがす
抄録
The objective of this study was to investigate the effects of the β3-adrenoceptor (AR) agonist ritobegron on rat bladder function following partial bladder outlet obstruction and on rat salivary secretion. In addition, the effects of ritobegron were compared with those of the anti-muscarinic agent tolterodine. After a 6-week partial bladder outlet obstruction (BOO), drug effects on bladder functions were evaluated using cystometrography. Effects on carbachol (CCh)-induced salivary secretion were evaluated in urethane-anesthetized rats. Ritobegron significantly decreased the frequency of non-voiding contractions (NVC), while both ritobegron and tolterodine each significantly decreased the amplitude of NVC. Ritobegron had no effect on either the micturition pressure (MP) or the residual volume (RV). In contrast, tolterodine dose-dependently decreased MP and increased RV. Ritobegron had no effect on CCh-induced salivary secretion, whereas tolterodine dose-dependently decreased it. Ritobegron decreased both the frequency and amplitude of NVC, which is similar to its effect on the contractions associated with detrusor overactivity (DO) in patients with an overactive bladder (OAB), without affecting MP, RV, or CCh-induced salivary secretion. Although tolterodine reduced the amplitude of NVC, it also markedly increased RV and significantly inhibited CCh-induced salivary secretion. These results suggest that use of ritobegron, a β3-AR agonist, is unlikely to lead to the residual urine and dry mouth symptoms that are associated with anti-muscarinic drugs, and that ritobegron may hold promise as a safe and effective agent for OAB treatment.<br>
収録刊行物
-
- Journal of Smooth Muscle Research
-
Journal of Smooth Muscle Research 48 (5_6), 115-124, 2012
日本平滑筋学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282680035299968
-
- NII論文ID
- 10031151478
-
- NII書誌ID
- AN10364204
-
- ISSN
- 18848796
- 09168737
-
- PubMed
- 23538508
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可